randomized trial comparing the impact of nonionic (iomeprol) versus an ionic (ioxaglate) low osmolar contrast medium on abrupt vessel closure and ischemic complications after coronary angioplasty

Objectives To assess the effect of nonionic versus ionic contrast medi on abrupt vessel closure and major ischemic complications after coronary angioplasty. Background There is continuous debate about the “thrombogenic potential” of nonionic contrast media. The results of both in vitro and in vivo investigations are incongruent. Methods We prospectively evaluated the outcomes of 2,000 patients undergoing percutaneous transluminal coronary angioplasty (PTCA). According to randomized, double-blind protocol, they received either iomeprol (nonionic; n = 1,001) or ioxaglate (ionic; n = 999). Intracoronary thrombus before PTC was found more often in the iomeprol group (4.2% vs 2.7%, p = 0.04). No other significant differences between both groups were observed with regard to pre-PTC clinical and angiographic characteristics. Results The frequency of reocclusions necessitating repeat angioplasty occurring either in laboratory (2.9% with iomeprol and 3.0% with ioxaglate) or out of laboratory (3.1% vs 4.1%) was not significantly different. The rate of major ischemic complications was also comparable after both contrast medi (emergency bypass surgery: 0.8% vs 0.7%, myocardial infarction: 1.8 vs 2.0%, cardiac death during hospital stay: 0.2% vs 0.2%). In the iomeprol group, more patients had dissections post-PTC (30.2% vs 25.0%, p = 0.01) and more patients received intracoronary stents (31.6% vs 25.7%, p = 0.004). Allergic reactions requiring treatment occurred only in the ioxaglate group (0.0% vs 0.9%, p = 0.002). Conclusions The nonionic contrast medium was not associated with higher rate of abrupt vessel closure requiring repeat angioplasty, or major ischemic events. These dat suggest that nonionic contrast medi do not increase the risk of thrombotic complications in patients undergoing coronary interventions.